Triazole modified cyclic peptide of amphibian-derived antibacterial peptide as well as preparation method and application of triazole modified cyclic peptide

By modifying amphibian antibacterial peptides and modifying them by clicking chemical method, Triazole-Cathelicidin-NV or Triazole-Cathelicidin-DM is formed, which solves the stability and cytotoxicity of natural antibacterial peptides, and improves antibacterial activity and biological phases. Capacity enables efficient synthesis and application of cyclic peptides.

CN118994352APending Publication Date: 2024-11-22RUNHUI BIOTECHNOLOGY (WEIHAI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411120711.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The cytotoxicity, stability and activity of natural-derived amphibian antibacterial peptides limits its application prospects, and the traditional cyclic peptide synthesis method is costly, high raw material consumption, and poor atomic economy.

Method used

By modifying the antibacterial peptides from amphibians, non-natural amino acid modifications were performed by click chemistry to form Triazole-Cathelicidin-NV or Triazole-Cathelicidin-DM, enhancing the anti-enzymatic ability and stability, and through hydrophobicity Synthesis was carried out by carrier method and solid-phase polypeptide synthesis method.

Benefits of technology

It improves antibacterial activity and biocompatibility, prolongs the half-life, enhances target affinity and proliferation activity of keratinocytes, and reduces cytotoxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994352A_ABST
    Figure CN118994352A_ABST
Patent Text Reader

Abstract

The invention discloses triazole modified cyclic peptide of antibacterial peptide derived from amphibians and a preparation method and application thereof.The preparation method comprises the steps that (2, 4-bis (octadecyloxy) phenyl) methanol, a catalyst, Fmoc-Lys (Boc)-OH, a solvent and a condensing agent are mixed in proportion and then subjected to amidation reaction to form a peptide bond, then the peptide bond is sequentially connected with other amino acids through the same method, and a linear peptide chain is obtained; and cyclizing the linear peptide chain through a click chemistry method, cracking the cyclized product, and removing (2, 4-bis (octadecyloxy) phenyl) methyl and amino acid protecting groups, thereby obtaining the 2, 4-bis (octadecyloxy) phenyl) methyl. Compared with naturally extracted polypeptides, the polypeptide has the advantages that disulfide bonds are replaced by 1, 2, 3-triazole, so that the enzymolysis resistance is greatly improved, the stability is improved, and the half-life period is prolonged; molecular docking shows that the target affinity is greatly improved, and proliferation of keratinocytes and fibroblasts can be enhanced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a triazole-modified cyclic peptide of an amphibian-derived antimicrobial peptide, and a preparation method and application thereof. Background Art

[0002] The statements herein merely provide background information related to the present invention and do not necessarily constitute prior art.

[0003] Amphibian antimicrobial peptides are a class of polypeptide substances with antimicrobial activity produced in amphibians. These antimicrobial peptides are usually extracted from the skin secretions of amphibians and have the characteristics of strong alkalinity, thermal stability and broad-spectrum antibacterial properties.

[0004] The mechanism of action of amphibian antimicrobial peptides is mainly to destroy the integrity of bacterial cell membranes, causing the bacterial contents to leak out and die. In addition, amphibian antimicrobial peptides also have synergistic effects and can work together with other antimicrobial substances to enhance the antibacterial effect. The study of amphibian antimicrobial peptides is of great significance for understanding the defense mechanism of organisms and developing new antimicrobial drugs. At present, some amphibian antimicrobial peptides have been used in the medical field to treat diseases such as bacterial infections.

[0005] However, due to the cytotoxicity, stability and activity of natural amphibian antimicrobial peptides, their application prospects still need further research and exploration.

[0006] Cathelicidin-NV, with the sequence ARGKKECKDDRCRLLMKRGSFSYV, is a disulfide bond cyclic peptide derived from the skin of the Chinese amphibian species Nanorana ventripunctata. In addition to its antibacterial, free radical scavenging, skin anti-photoaging and antioxidant activities, it also has repair activity. The black-spotted toad has a strong ability to adapt to the environment. Cathelicidin-DM, with the sequence SSRRKPCKGWLCKLKLRGGYTLIGSATNLNRPTYVRA, is a disulfide bond cyclic peptide derived from the skin of the black-spotted toad (Duttaphrynus melanostictus). It has a broad-spectrum antimicrobial activity, chemotaxis for immune cells, induction of mast cell degranulation and histamine release, promotion of angiogenesis, accelerated wound healing, induction of lymphocyte activation and apoptosis of mutant cell lines, etc.

[0007] The disulfide bonds in the above two peptides have a stabilizing effect in the peptides, but the disulfide bonds themselves are quite unstable. Disulfide isomerases and reducing agents will affect this covalent bond, causing structural rearrangement and loss of activity. Moreover, when using peptides, the disulfide bridge is easily metabolized and chemically degraded. In addition, natural peptides have some other defects, such as cytotoxicity and instability that can be easily hydrolyzed by proteases, and the direct use of natural peptides is still subject to many restrictions.

[0008] In addition, the current synthesis of linear precursor peptides of cyclic peptides mostly uses solid-phase synthesis, which is usually very expensive. The reaction is a heterogeneous reaction and requires at least twice the equivalent of amino acid raw materials. A large amount of solvent is needed to wash the resin during the reaction. At the same time, the TLC method cannot be used to effectively monitor the reaction progress and impurity generation. A large amount of raw materials and solvents are consumed, the atom economy is poor, and the production cost is high. Summary of the invention

[0009] In view of the shortcomings of the prior art, the purpose of the present invention is to provide a triazole-modified cyclic peptide of amphibian-derived antimicrobial peptide and its preparation method and application. The non-natural amino acid modification of amphibian-derived antimicrobial peptide can enhance its ability to resist enzymatic hydrolysis, thereby increasing stability and prolonging half-life.

[0010] In order to achieve the above object, the present invention is implemented through the following technical solutions:

[0011] In the first aspect, the present invention provides a triazole-modified cyclic peptide of an amphibian-derived antimicrobial peptide, which is Triazole-Cathelicidin-NV or Triazole-Cathelicidin-DM, and its structural formula is as follows:

[0012]

[0013] In a second aspect, the present invention provides a method for preparing a triazole-modified cyclic peptide Triazole-Cathelicidin-NV of an amphibian-derived antimicrobial peptide, comprising the following steps:

[0014] After (2,4-bis(octadecyloxy)phenyl)methanol, a catalyst, Fmoc-Val-OH, a solvent and a condensing agent were mixed in proportion, an amidation reaction was carried out to form a peptide bond, and then Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Phe-OH, Fmoc-Ser(tBu)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-Le u-OH, Fmoc-Arg(Pbf)-OH, Fmoc-PRA-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmo c-L-DAP(N3)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH and Fmoc-Ala-OH;

[0015] The prepared linear peptide product was cyclized by click chemistry;

[0016] The cyclized product is cleaved, and the (2,4-bis(octadecyloxy)phenyl)methyl group and the amino acid protecting group are removed to obtain the compound.

[0017] In a third aspect, the present invention provides a method for preparing a triazole-modified cyclic peptide Triazole-Cathelicidin-DM of an amphibian-derived antimicrobial peptide, comprising the following steps:

[0018] After (2,4-bis(octadecyloxy)phenyl)methanol, a catalyst, Fmoc-Ala-OH, a solvent and a condensing agent are mixed in proportion, an amidation reaction is carried out to form a peptide bond, and then Fmoc-Arg(Pbf)-OH, Fmoc-Val-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Leu-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Ala-OH, Fmoc-Ser(tBu)-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Thr(tBu)- OH, Fmoc-Tyr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc -Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Leu-OH, Fmoc-T rp(Boc)-OH, Fmoc-Gly-OH, Fmoc-Lys(Boc)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Pro-OH, Fmoc-Lys (Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ser(tBu)-OH, and Fmoc-Ser(tBu)-OH;

[0019] The prepared linear peptide product was cyclized by click chemistry;

[0020] The cyclized product is cleaved, and the (2,4-bis(octadecyloxy)phenyl)methyl group and the amino acid protecting group are removed to obtain the compound.

[0021] In some embodiments, the solvent is dichloromethane, methyltetrahydrofuran, or acetonitrile.

[0022] In some embodiments, after the amidation reaction of (2,4-bis(octadecyloxy)phenyl)methanol and Fmoc-Lys(Boc)-OH, Fmoc-Val-OH or Fmoc-Ala-OH is completed, the step of adding 4-methylpiperidine to react is further included.

[0023] In a fourth aspect, the present invention provides the use of triazole-modified cyclic peptide Triazole-Cathelicidin-NV or Triazole-Cathelicidin-DM of amphibian-derived antimicrobial peptide in the preparation of medical products, skin care products or cosmetics.

[0024] The medical products, skin care products and cosmetics are used for anti-aging, wrinkle removal, scar removal, freckle removal and skin lightening.

[0025] In a fifth aspect, the present invention provides a composition comprising the triazole-modified cyclic peptide of the amphibian-derived antimicrobial peptide and a carrier.

[0026] In some embodiments, in the composition, the mass percentage of the triazole-modified cyclic peptide of the amphibian-derived antimicrobial peptide is 0.1%-90%; preferably 0.1%-80%; further preferably 0.1%-70%; further preferably 0.1%-50%; and can be 1%-40%.

[0027] In some embodiments, the carrier includes an oil phase, an aqueous phase, and / or an excipient.

[0028] Preferably, the oil phase is selected from one or a combination of vegetable oil, animal oil, fat, higher fatty acid, ester, hydrocarbon, wax or higher alcohol.

[0029] Preferably, the excipient is selected from one or a combination of a binder, a filler, a disintegrant, a preservative, a chelating agent, a thickener, a gelling agent, an emollient, an emulsifier, an antioxidant, a penetration enhancer or a stabilizer.

[0030] Preferably, the composition is in the form of a solution, gel, emulsion, cream, paste, plaster, ointment, lyophilized powder, patch, suspension, wipe or foam.

[0031] The beneficial effects achieved by one or more embodiments of the present invention are as follows:

[0032] The three non-natural amino acid modified cyclic peptides provided by the present invention have improved antibacterial activity and reduced cytotoxicity, thereby improving their safety and biocompatibility;

[0033] Compared with naturally extracted polypeptides, the present invention uses 1,2,3-triazole to replace the disulfide bond, which greatly improves the resistance to enzymatic hydrolysis, thereby increasing its stability and prolonging its half-life; molecular docking shows that its target affinity is greatly improved, and it is predicted that the activity of activated protein kinase is increased, which can enhance the proliferation of keratinocytes and fibroblasts. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0035] Figure 1 is the mass spectrum of Triazole-Cathelicidin-NV prepared in Example 1 of the present invention;

[0036] Figure 2 is the mass spectrum of Triazole-Cathelicidin-DM prepared in Example 1 of the present invention;

[0037] Figure 3 The cytotoxicity comparison test results of the modified cyclic peptides prepared in the examples of the present invention are shown in Figure 1, wherein A is a cytotoxicity comparison chart of Triazole-Cathelicidin-NV and Cathelicidin-NV; B is a cytotoxicity comparison chart of Triazole-Cathelicidin-DM and Cathelicidin-DM;

[0038] Figure 4 The results of the plasma stability comparison experiment of the modified cyclic peptides prepared in the examples of the present invention are shown in Figure 1, wherein A is a plasma stability comparison chart of Triazole-Cathelicidin-NV and Cathelicidin-NV; B is a plasma stability comparison chart of Triazole-Cathelicidin-DM and Cathelicidin-DM;

[0039] Figure 5 are the results of docking of the modified cyclic peptide prepared in the embodiment of the present invention with the protein kinase molecule, wherein A is (the result of docking of Cathelicidin-NV with P38 protein kinase molecule); B is (the result of docking of Triazole-Cathelicidin-NV with P38 protein kinase molecule); C is (the result of docking of Cathelicidin-DM with P38 protein kinase molecule); D is (the result of docking of Triazole-Cathelicidin-DM with P38 protein kinase molecule); E is (the result of docking of Cathelicidin-NV with ERK protein kinase molecule); F is (the result of docking of Triazole-Cathelicidin-NV with ERK protein kinase molecule); G is (the result of docking of Cathelicidin-DM with ERK protein kinase molecule); H is (the result of docking of Triazole-Cathelicidin-DM with ERK protein kinase molecule);

[0040] Figure 6This is a graph showing the effect of Cathelicidin-NV on the proliferation rate of HaCaT cells and HUVEC cells in an embodiment of the present invention;

[0041] Figure 7 This is a graph showing the effect of Triazole-Cathelicidin-NV on the proliferation rate of HaCaT cells and HUVEC cells in an embodiment of the present invention;

[0042] Figure 8 The effect of Cathelicidin-DM on the proliferation rate of HaCaT cells and HUVEC cells in the examples of the present invention;

[0043] Fig. 9 1 is the effect of Triazole-Cathelicidin-DM on the proliferation rate of HaCaT cells and HUVEC cells in the examples of the present invention. DETAILED DESCRIPTION

[0044] It should be noted that the following detailed descriptions are illustrative and intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0045] The present invention will be further described below in conjunction with the embodiments.

[0046] Example 1: Synthesis of Triazole-Cathelicidin-NV by Hydrophobic Support Method

[0047] In a 1000ml round-bottom flask, add 6.45g (10mmol, 1.0eq) of (2,4-bis(octadecyloxy)phenyl)methanol (TAG), 15mmol (1.5eq) of Fmoc-Val-OH, 20mmol (2.0eq) of DMAP and 200ml of methyltetrahydrofuran, stir until dissolved, add 20mmol (2.0eq) of DIC dropwise, react at 25℃ for 4 hours, and the reaction is complete when detected by TLC. Wash three times with 200ml of saturated ammonium chloride aqueous solution and saturated brine in sequence.

[0048] 4.00 g (2%) of 4-methylpiperidine was added, and the mixture was reacted at 25°C for 4 hours. The reaction was complete when detected by TLC. The mixture was washed three times with 200 ml of saturated ammonium chloride aqueous solution and saturated brine.

[0049] Next, connect Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Phe-OH, Fmoc-Ser(tBu)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-O H, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-PRA-OH, Fmoc-Arg(Pbf)- OH, Fmoc-Asp(OtBu)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-L-DAP(N3)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH and Fmoc-Ala-OH. The connection method, reagent equivalents and post-treatment are consistent with those for connecting Fmoc-Val-OH.

[0050] After the organic phase was concentrated to dryness, 10.0 mmol of cuprous iodide, 30.0 mmol of ascorbic acid, 80.0 mmol of N,N-diisopropylethylamine and 600 mL of acetonitrile were added to the round-bottom flask. The reaction system was a suspension and the reaction was carried out at 25°C for 72 hours. The reaction was complete when detected by TLC. The solid was filtered, washed and dried to obtain an off-white solid.

[0051] The above-mentioned off-white solid and 300 mL of lysis solution (TFA: Tis: H2O: EDT = 95: 2: 2: 1) were added to the round-bottom flask. The mixture was stirred and lysed for three hours. After the lysis was completed, the lysate was dried by spin drying, and the dried liquid was released into 500 mL of methyl tert-butyl ether and stirred for half an hour to produce a large amount of white precipitate. The mixture was then filtered and the filter cake was washed with methyl tert-butyl ether for several times and dried by nitrogen.

[0052] The crude peptide was purified by reverse phase HPLC using a C18 preparative column (50*250mm, 10μm). Mobile phase A was 0.1% trifluoroacetic acid / water solution and mobile phase B was 0.1% trifluoroacetic acid / acetonitrile solution. The UV detection wavelength was 203nm. After concentration and freeze drying, 12.0g of pure product was obtained with a purity of 97.8% and a total yield of 42.3%. The mass spectrum of Triazole-Cathelicidin-NV is shown in Figure 1 .

[0053] The process synthesis route is as follows:

[0054]

[0055] Example 2: Synthesis of Triazole-Cathelicidin-DM by Hydrophobic Carrier Method

[0056] In a 500 ml round-bottom flask, add (2,4-bis(octadecyloxy)phenyl)methanol (TAG) 6.45 g (10 mmol, 1.0 eq), Fmoc-Ala-OH 15 mmol (1.5 eq), DMAP 20 mmol (2.0 eq) and methyltetrahydrofuran 200 ml, stir until dissolved, add DIC 20 mmol (2.0 eq) dropwise, react at 25 ° C for 4 hours, and the reaction is complete when detected by TLC.

[0057] Wash three times with 200 ml saturated ammonium chloride aqueous solution and saturated brine in sequence. Add 4.00 g (2%) of 4-methylpiperidine and react at 25°C for 4 hours. TLC indicates that the reaction is complete. Wash three times with 200 ml saturated ammonium chloride aqueous solution and saturated brine in sequence.

[0058] Next, connect Fmoc-Arg(Pbf)-OH, Fmoc-Val-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Leu-OH, Fmoc-Asn(Trt)-OH in order , Fmoc-Thr(tBu)-OH, Fmoc-Ala-OH, Fmoc-Ser(tBu)-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Thr(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc -Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Leu-OH, Fmoc-Trp(Boc)-OH, Fmoc-Gly-OH, Fmoc-Lys(Boc)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Pro-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ser(tBu)-OH, and Fmoc-Ser(tBu)-OH. The connection method, reagent equivalents, and post-treatment are consistent with those for connecting Fmoc-Ala-OH.

[0059] After the organic phase was concentrated to dryness, 10.0 mmol of cuprous iodide, 30.0 mmol of ascorbic acid, 80.0 mmol of N,N-diisopropylethylamine and 600 mL of acetonitrile were added to the round-bottom flask. The reaction system was a suspension and the reaction was carried out at 25°C for 72 hours. The reaction was complete when detected by TLC. The solid was filtered, washed and dried to obtain an off-white solid.

[0060] The above-mentioned off-white solid and 500 mL of lysis solution (TFA: Tis: H2O: EDT = 95: 2: 2: 1) were added to the round-bottom flask. The mixture was stirred and lysed for three hours. After the lysis was completed, the lysate was dried by spin drying, and the dried liquid was released into 800 mL of methyl tert-butyl ether and stirred for half an hour to produce a large amount of white precipitate. The mixture was then filtered and the filter cake was washed with methyl tert-butyl ether for several times and dried by nitrogen.

[0061] The crude peptide was purified by reverse phase HPLC using a C18 preparative column (50*250mm, 10μm). Mobile phase A was 0.1% trifluoroacetic acid / water solution and mobile phase B was 0.1% trifluoroacetic acid / acetonitrile solution. The UV detection wavelength was 203nm. After concentration and freeze drying, 9.00g of pure product was obtained with a purity of 97.6% and a total yield of 21.6%. The mass spectrum of Triazole-Cathelicidin-DM is shown in Figure 1 The process synthesis route is as follows:

[0062]

[0063] Comparative Example 1: Synthesis of Triazole-Cathelicidin-NV by Solid Phase Peptide Synthesis

[0064] The linear peptide was synthesized by the traditional Fmoc-protected solid-phase peptide synthesis method, and Triazole-Cathelicidin-NV was obtained by cyclization after cleavage. CTC resin was selected as the solid phase carrier. First, the resin was activated, 9g CTC resin (loading amount was 1.11mmol / g) was weighed, swelled with 100mL DCM for 1 hour at room temperature, and then the swelling liquid was filtered, and the resin was washed three times with 100mL DMF and 100mL DCM. 30mmol Fmoc-Val-OH and 30mmol DIEA were stirred and dissolved with a small amount of DCM, and added to the reaction bottle for 2 hours. 100mL DIEA:MeOH:DCM (1:1:4) mixed solution was measured for capping, reacted for half an hour, filtered the reaction solution, washed three times with DMF, and filtered. 200mL 20% PIP / DMF was added twice to remove Fmoc, the first time for 5 minutes and the second time for 10 minutes. Then the ninhydrin test was performed, the solution was dark blue, the resin was yellow, and the reaction was complete. Weigh 30mmol Fmoc-Tyr(tBu)-OH, 30mmol HOBt, 30mmol DIC, stir and dissolve, add to the reaction system, test with ninhydrin, the solution is light yellow, the resin is colorless, the reaction is complete, filter the reaction solution, wash the resin with DMF three times, keep it overnight for the last time, add 200mL 20% PIP / DMF to remove Fmoc, twice, the first time for 5 minutes, the second time for 10 minutes. Test with ninhydrin, the solution is dark blue, the resin is colorless, wash the resin with DMF, wash until the pH test is neutral.Continue to inspect, wash and swell according to the above steps, and condense Fmoc-Ser(tBu)-OH, Fmoc-Phe-OH, Fmoc-Ser(tBu)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-PRA-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-L-DAP(N3)-OH, Fmoc-Met-OH Fmoc-Glu(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH and Fmoc-Ala-OH were used to synthesize H-Ala-Arg(Pbf)-Gly-Lys(Boc)-Lys(Boc)-Glu(OtBu)-DAP(N3)-Lys(Boc)-Asp(OtBu)-Asp(OtBu)-Arg(Pbf)-PRA-Arg(Pbf)-Leu-Leu-Met-Lys(Boc)-Arg(Pbf)-Gly-Ser(tBu)-Phe-Ser(tBu)-Tyr(tBu)-Val-CTC. The resin was shrunk with 100 mL of methanol, washed three times, and then the resin was drained and dried. The dried resin was placed in a round-bottom flask, and 200 mL of lysis solution (TFA: Tis: H2O: EDT = 95: 2: 2: 1) was added. The mixture was stirred and lysed for three hours. After the lysis was completed, the lysate was dried by spin drying, and the dried liquid was released into 600 mL of methyl tert-butyl ether and stirred for half an hour to produce a large amount of white precipitate, which was then filtered and the filter cake was washed with methyl tert-butyl ether for several times. Finally, the filter cake was lyophilized and purified by chromatography to obtain the linear peptide H-Ala-Arg-Gly-Lys-Lys-Glu--DAP(N3)-Lys-Asp-Asp-Arg-PRA-Arg-Le u-Leu-Met-Lys-Arg-Gly-Ser-Phe-Ser-Tyr-Val-OH. The linear peptide was dissolved in water at a peptide concentration of 1 g / L, and 10.0 mmol copper sulfate (II) pentahydrate, 30.0 mmol sodium ascorbate and 80.0 mmol N,N-diisopropylethylamine were added, and stirred until the mass spectrometry reaction was complete. After the reaction was completed, freeze-dried.The crude peptide was purified by reverse phase HPLC using a C18 preparative column (50*250 mm, 10 μm), with mobile phase A being 0.1% trifluoroacetic acid / water solution and mobile phase B being 0.1% trifluoroacetic acid / acetonitrile solution. The UV detection wavelength was 203 nm. After concentration and freeze drying, 7.79 g of pure product was obtained, with a purity of 96.8% and a yield of 27.3%.

[0065] The process synthesis route is as follows:

[0066]

[0067] Comparative Example 2: Synthesis of Triazole-Cathelicidin-DM by Solid Phase Peptide Synthesis

[0068] The linear peptide was synthesized by the traditional Fmoc-protected solid-phase peptide synthesis method, and Triazole-Cathelicidin-DM was obtained by cyclization after cleavage. CTC resin was selected as the solid phase carrier. First, the resin was activated, 9g CTC resin (loading amount was 1.11mmol / g) was weighed, swelled with 100mL DCM for 1 hour at room temperature, and then the swelling liquid was filtered, and the resin was washed three times with 100mL DMF and 100mL DCM. 30mmol Fmoc-Ala-OH and 30mmol DIEA were stirred and dissolved with a small amount of DCM, and added to the reaction bottle for 2 hours. 100mL DIEA:MeOH:DCM (1:1:4) mixed solution was measured for capping, reacted for half an hour, filtered the reaction solution, washed three times with DMF, and filtered. 200mL 20% PIP / DMF was added twice to remove Fmoc, the first time for 5 minutes and the second time for 10 minutes. Then the ninhydrin test was performed, the solution was dark blue, the resin was yellow, and the reaction was complete. Weigh 30mmol Fmoc-Arg(Pbf)-OH, 30mmol HOBt, 30mmol DIC, stir and dissolve, add to the reaction system, test with ninhydrin, the solution is light yellow, the resin is colorless, the reaction is complete, filter the reaction solution, wash the resin with DMF three times, keep it overnight for the last time, add 200mL 20% PIP / DMF to remove Fmoc, twice, the first time for 5 minutes, the second time for 10 minutes. Test with ninhydrin, the solution is dark blue, the resin is colorless, wash the resin with DMF, wash until the pH test is neutral.Continue to check, wash and swell according to the above steps, and condense Fmoc-Val-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Leu-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Ala-OH, Fmoc-Ser(tBu)-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Thr(tBu)-OH, Fmoc -Tyr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmo c-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-L-DAP(N3)-OH, Fmoc-Leu-OH, Fmoc-Trp(Boc)-OH, Fmoc-Gly-OH, F moc-Lys(Boc)-OH, Fmoc-PRA-OH, Fmoc-Pro-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf )-OH, Fmoc-Ser(tBu)-OH, and Fmoc-Ser(tBu)-OH to obtain NH2-Ser(tBu)-Ser(tBu)-Arg(Pbf)-Arg(Pbf)-Lys(Boc)-Pro-PRA-Lys(Boc)-Gly-Trp(Boc)-Leu-DAP(N3)-Lys(Boc)-Leu-Lys(Boc)-Leu-Arg(Pbf)-Gl y-Gly-Tyr(tBu)-Thr(tBu)-Leu-Ile-Gly-Ser(tBu)-Ala-Thr(tBu)-Asn(Trt)-L eu-Asn(Trt)-Arg(Pbf)-Pro-Thr(tBu)-Tyr(tBu)-Val-Arg(Pbf)-Ala-CTC The resin was shrunk with 100 mL of methanol, washed three times, and then the resin was drained and dried. The dried resin was placed in a round-bottom flask and 200 mL of lysis solution (TFA:Tis:H2O:EDT=95:2:2:1) was added.The mixture was stirred and lysed for three hours. After the lysis was completed, the lysate was dried by spin drying. The dried liquid was released into 800 mL of methyl tert-butyl ether and stirred for half an hour to produce a large amount of white precipitate. The mixture was then filtered and the filter cake was washed several times with methyl tert-butyl ether. Finally, the filter cake was freeze-dried and purified by chromatography to obtain a linear peptide H-Ser-Ser-Arg-Arg-Lys-Pro-PRA-Lys-Gly-Trp-Leu-DAP(N3)-Lys-Leu-Lys-Leu-Arg-Gly-Gly-Tyr-Thr-Leu-Ile-Gly-Ser-Ala-Thr-Asn-Leu-Asn-Arg-Pro-Thr-Tyr-Val-Arg-Ala-OH. Dissolve the linear peptide in water at a peptide concentration of 1g / L, add 10.0mmol copper sulfate (II) pentahydrate, 30.0mmol sodium ascorbate and 80.0mmol N,N-diisopropylethylamine, and stir until the mass spectrometry reaction is complete. After the reaction is completed, freeze-dry. Use a C18 preparative column (50*250mm, 10μm) to purify the crude peptide by reverse phase high performance liquid chromatography, mobile phase A is 0.1% trifluoroacetic acid / water solution, and mobile phase B is 0.1% trifluoroacetic acid / acetonitrile solution. The ultraviolet detection wavelength is 203nm. After concentration and freeze-drying, 5.99g of pure product was obtained, with a purity of 96.9% and a yield of 14.4%.

[0069] The process synthesis route is as follows:

[0070]

[0071] Table 1 Statistics of cyclopeptide synthesis results

[0072]

[0073] Antibacterial experiment

[0074] Minimum inhibitory concentration experiment:

[0075] The Clinical and Laboratory Standards Institute (CLSI) microdilution method was used to determine the minimum inhibitory concentration (MIC) of antimicrobial peptides. The same bacteria have different sensitivities to different antimicrobial peptides. The lower the MIC value, the higher the antimicrobial activity of the antimicrobial peptide. The purified Staphylococcus aureus was inoculated into LB (Luria-Bertani) liquid medium, cultured at 37°C overnight and transferred to a new LB medium for 5 hours. When the bacteria reached the logarithmic growth phase, they were washed three times with PBS (phosphate buffered salin), and the bacteria were suspended to prepare a concentration of 1×10 6CFU / mL of the test bacterial solution. Use the two-fold dilution method to transfer the antimicrobial peptide solution of different concentrations after doubling dilution to a 96-well cell culture plate, add an equal amount of bacterial suspension to the wells, about 100 μL per well, and repeat 3 times in parallel. The suspension containing bacterial solution but not antimicrobial peptides was set as the control group and incubated at 37°C for 18 hours. The minimum inhibitory concentration was considered to be when there was no turbidity at the bottom of the well with the naked eye.

[0076] The experimental steps for other bacteria are the same as above.

[0077] Inhibition zone experiment:

[0078] The purified Staphylococcus aureus was inoculated into LB liquid medium, cultured at 37°C overnight and transferred to new LB medium for 24 hours. Diluted with purified water to 1.0×10 6 CFU / mL, use a pipette to accurately measure 2ml and add it to a culture dish with an Oxford cup placed horizontally in advance. After solidification, dry the water in the culture dish thoroughly, remove the Oxford cup to complete the drilling, and add 20μL (concentration of 0.1g / L) of antimicrobial peptide solution to each hole. Place it in a 37℃ constant temperature incubator for 24 hours, observe and measure the diameter of the inhibition zone, and use a group without adding peptide as a blank control group.

[0079] The experimental steps for other bacteria are the same as above.

[0080] As shown in Table 2, the antibacterial concentration of Triazole-Cathelicidin-NV is lower than that of Cathelicidin-NV before modification; the antibacterial concentration of Triazole-Cathelicidin-DM is lower than that of Cathelicidin-DM before modification. The four cyclic peptides have good inhibitory effects on both Gram-positive and Gram-negative bacteria, and the effect on Gram-positive bacteria is better than that on Gram-negative bacteria. The diameter of the inhibition zone of Triazole-Cathelicidin-NV and Triazole-Cathelicidin-DM is larger than that of Cathelicidin-NV and Cathelicidin-DM, and the length of the diameter is almost twice that of Cathelicidin-NV and Cathelicidin-DM, which also verifies that the antibacterial ability of Triazole-Cathelicidin-NV and Triazole-Cathelicidin-DM is stronger than that of Cathelicidin-NV and Cathelicidin-DM.

[0081] Table 2 Antimicrobial activity of antimicrobial peptides against different bacteria

[0082]

[0083]

[0084] Cytotoxicity assay

[0085] HaCaT (human immortalized keratinocytes) were selected and cultured in high-glucose DMEM (dulbecco's modified eagle medium) containing 10% calf serum and 1% penicillin-streptomycin. The cells were transferred to an incubator at 37°C and 5% carbon dioxide for overnight culture. After 24 hours, the cell growth status was observed and the medium was changed or subcultured. After the culture was completed, the cell suspension was added to a 96-well cell culture plate, and the cell count per well reached 1×10 4 . Add different concentrations of cyclic peptide (final concentration 1-128μg / mL) after multiple dilution to the cell culture and incubate for 24 hours. After the culture is completed, add 10μl of MTT solution to each well and continue incubation at 37°C for 4 hours. Remove the supernatant in the well, add 150μl DMSO (dimethyl sulfoxide), and shake for 10 minutes to dissolve the purple crystals. On the microplate reader, measure the light absorption value (OD value) of each well at a wavelength of 490nm, and calculate the cell survival rate according to the following formula.

[0086] Cell survival rate % = (absorbance of experimental group / absorbance of control group) × 100%;

[0087] pass Figure 3 It can be seen that the cell survival rate of the Triazole-Cathelicidin-NV of the present invention is higher than that of the Cathelicidin-NV before modification. When the concentration of Cathelicidin-NV and Triazole-Cathelicidin-NV is lower than 128 μg / mL, the cell survival rate is above 70%, indicating that the two cyclic peptides have high biocompatibility with mammalian cells. Among them, the cytotoxicity of Triazole-Cathelicidin-NV is lower and the biocompatibility with mammals is higher. This shows that the Triazole-Cathelicidin-NV in the present invention is relatively non-toxic to cells at a concentration lower than 128 μg / mL, relatively safe, and has high biocompatibility with mammals, and both safety and biocompatibility are improved than Cathelicidin-NV.

[0088] pass Figure 3It can be seen that the cell survival rate of Triazole-Cathelicidin-DM in the present invention is higher than that of Cathelicidin-DM before modification. When the concentration of Cathelicidin-DM and Triazole-Cathelicidin-DM is lower than 128 μg / mL, the cell survival rate is above 70%, indicating that the two cyclic peptides have high biocompatibility with mammalian cells. Among them, Triazole-Cathelicidin-DM has lower cytotoxicity and higher biocompatibility with mammals. This shows that Triazole-Cathelicidin-DM in the present invention is relatively non-toxic to cells at a concentration lower than 128 μg / mL, relatively safe, and has high biocompatibility with mammals, and its safety and biocompatibility are both improved than Cathelicidin-DM.

[0089] Plasma stability test

[0090] This experiment conducted a series of experiments on the plasma stability of the four cyclic peptides. First, the mouse plasma containing the cyclic peptide was diluted (8-week-old male ICR mice were selected, and sodium heparin was selected as the anticoagulant), diluted to 0.01g / mL, incubated at 37°C, and 100μL was sampled every 12 hours, and ended after 36 hours. 4% phosphoric acid was added to the sample for protein precipitation, vortexed for 3 minutes, and centrifuged at 12000rpm for 10 minutes at 4°C. The supernatant was taken for content determination in LC-MS / MS.

[0091] Through Table 3 and Figure 4 It can be seen that compared with the natural amino acid cyclic peptides Cathelicidin-NV and Cathelicidin-DM, the 1,2,3-triazole modified cyclic peptides Triazole-Cathelicidin-NV and Triazole-Cathelicidin-DM have significantly improved stability in plasma. Plasma stability experiments show that replacing disulfide bonds with 1,2,3-triazole improves the stability of cyclic peptides. The application of natural amino acid peptides in the human body has the disadvantages of being easily hydrolyzed by enzymes and having poor biological stability, which brings inconvenience to their application. Both disulfide isomerases and reducing agents will affect the stability of disulfide bridges, leading to structural rearrangement and loss of activity, and when peptides are used, disulfide bonds are easily metabolized and chemically degraded.

[0092] Table 3 Residual rate of cyclic peptides after different incubation times

[0093]

[0094] Molecular docking studies

[0095] Protein / receptor preparation:

[0096] The crystal structure of p38 in complex with SR72 (PDB ID-6Y4X) and the structure of ERK in complex with the dual inhibitor astx 029 (PDB ID-7AUV) were downloaded from the Collaborative Laboratory for Structural Research Bioinformatics (RCSB), Protein Data Bank (www.rcsb.org), in pdf format. Before detailed docking analysis, proteins were first prepared using the AutoDock tool. Both protein complexes were selected by embedding ligands. Ligand removal, water removal, hydrogenation and other operations were performed by the software. Finally, the resulting biomacromolecules were saved in pdb format.

[0097] Cathelicidin-NV, Triazole-Cathelicidin-NV, Cathelicidin-DM and Triazole-Cathelicidin-DM were converted into 3D models using Chem3D and saved as "Pdb" format files.

[0098] Cathelicidin-NV, Triazole-Cathelicidin-NV, Cathelicidin-DM and Triazole-Cathelicidin-DM were used as ligands for molecular docking, and p38 and ERK were used as receptors for molecular docking. Molecular docking was performed on HDOCKSERVER (http: / / hdock.phys.hust.edu.cn / ), and the predicted binding model was generated. Finally, Pymol software was used to further analyze their binding mode, binding affinity and critical interaction.

[0099] like Figure 5As shown, the docking results with p38 protein kinase showed that the Cathelicidin-NV molecule formed hydrogen bonds with amino acid residues HIS199, ASP145, GLU328, ARG67 and GLN60, and Triazole-Cathelicidin-NV formed multiple pairs of hydrogen bonds with amino acid residues GLN60, ARG67, ARG70, ASP168, ARG149 and HIS199; the Cathelicidin-DM molecule formed hydrogen bonds with amino acid residues LEU278, LYS272, GLY242, and HIS269, and Triazole-Cathelicidin-DM formed multiple pairs of hydrogen bonds with amino acid residues TYR258, ILE229, LEU195, ASN196, MET198, TYR200, ILE147, ASP145, and SER329. The docking results with ERK2 protein kinase showed that the Cathelicidin-NV molecule formed multiple pairs of hydrogen bonds with amino acid residues TYR113, SER153, ARG191, GLN66, TYR205, ASP336 and ASP337, and Triazole-Cathelicidin-NV formed multiple pairs of hydrogen bonds with TYR113, SER153, ARG191, ASP336, GLN66, ARG148, ASP337 and TYR205; the Cathelicidin-DM molecule formed hydrogen bonds with amino acid residues LEU278, ARG277, LYS272, GLY242 and HIS269, and Triazole-Cathelicidin-DM formed multiple pairs of hydrogen bonds with amino acid residues ASP124, HIS125, THR160, THR159, ASP162, ASN158, VAL49, LYS48 and ASN27. Hydrogen bonding is a crucial part of the activity between proteins and ligands. After the modification, the number of hydrogen bonds formed between the cyclic peptide molecule and protein kinase increased significantly.

[0100] The Docking Score is evaluated based on the affinity between molecular pairs. Affinity refers to the ability of molecules to interact with each other, including van der Waals forces, hydrogen bonds, ionic bonds, etc. The stronger the affinity, the tighter the binding between molecules and the more stable the interaction. The Docking Score evaluates affinity by calculating the interaction energy between molecules. The lower the calculated Docking Score, the stronger the affinity between molecules. As can be seen from Table 4, the Docking Scores of the cyclic peptides modified with triazole are all reduced, indicating that the affinity is enhanced.

[0101] Table 4 Scoring results of docking of cyclic peptides with protein kinases

[0102]

[0103] Promotes fibroblast proliferation activity

[0104] HaCaT, HUVEC (human umbilical vein endothelial cells) and HSF (human skin fibroblasts) were cultured in high-glucose DMEM containing 10% calf serum and 1% penicillin-streptomycin. The cells were transferred to an incubator at 37°C and 5% carbon dioxide for overnight culture. The next day, the cell growth status was observed and the medium was changed or subcultured. After the culture was completed, the cell suspension was added to a 96-well cell culture plate, and the cell count per well reached 1×10 4 indivual.

[0105] Cells in logarithmic growth phase were taken and different concentrations of cyclopeptide (final concentration 2.5, 5, 10 and 20 μg / mL) were added to the cell culture of the experimental group for 24 hours. The proliferation rate of HaCaT cells, HUVEC cells and HSF cells was detected by MTT method.

[0106] pass Figure 6 and Figure 7 It can be seen that, compared with the control group, at a concentration of 20 μg / mL, after 24 hours, the proliferation rate of HaCaT by Triazole-Cathelicidin-NV of the present invention increased to 161%, which is better than 146% of Cateliciin-NV; the proliferation rate of HUVEC increased to 168%, which is better than 159% of Cathelicidin-NV. Compared with the control group, at a concentration of 20 μg / mL, after 24 hours, the proliferation rate of HaCaT by Triazole-Cathelicidin-DM of the present invention increased to 196%, Cathelicidin-DM increased to 171%, and the proliferation rate of HUVEC increased to 250%, which is better than 220% of Cathelicidin-DM. Figure 8 and Fig. 9 shown.

[0107] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A triazole-modified cyclic peptide of an amphibian-derived antimicrobial peptide, characterized in that: It is Triazole-Cathelicidin-NV or Triazole-Cathelicidin-DM, and its structural formula is as follows:

2. The method for preparing the triazole-modified cyclic peptide Triazole-Cathelicidin-NV of the amphibian-derived antimicrobial peptide according to claim 1, characterized in that: The steps include: After (2,4-bis(octadecyloxy)phenyl)methanol, a catalyst, Fmoc-Val-OH, a solvent and a condensing agent were mixed in proportion, an amidation reaction was carried out to form a peptide bond, and then Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Phe-OH, Fmoc-Ser(tBu)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-Le u-OH, Fmoc-Arg(Pbf)-OH, Fmoc-PRA-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmo c-L-DAP(N3)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH and Fmoc-Ala-OH; The prepared linear peptide product was cyclized by click chemistry; The cyclized product is cleaved, and the (2,4-bis(octadecyloxy)phenyl)methyl group and the amino acid protecting group are removed to obtain the compound.

3. The method for preparing the triazole-modified cyclic peptide Triazole-Cathelicidin-DM of the amphibian-derived antimicrobial peptide according to claim 1, characterized in that: The steps include: After (2,4-bis(octadecyloxy)phenyl)methanol, a catalyst, Fmoc-Ala-OH, a solvent and a condensing agent are mixed in proportion, an amidation reaction is carried out to form a peptide bond, and then Fmoc-Arg(Pbf)-OH, Fmoc-Val-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Leu-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Ala-OH, Fmoc-Ser(tBu)-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Thr(tBu)- OH, Fmoc-Tyr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc -Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Leu-OH, Fmoc-T rp(Boc)-OH, Fmoc-Gly-OH, Fmoc-Lys(Boc)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Pro-OH, Fmoc-Lys (Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ser(tBu)-OH, and Fmoc-Ser(tBu)-OH; The prepared linear peptide product was cyclized by click chemistry; The cyclized product is cleaved, and the (2,4-bis(octadecyloxy)phenyl)methyl group and the amino acid protecting group are removed to obtain the compound.

4. The preparation method according to any one of claims 2 to 4, characterized in that: The solvent is dichloromethane, methyltetrahydrofuran or acetonitrile.

5. The preparation method according to any one of claims 2 to 4, characterized in that: After the amidation reaction of (2,4-bis(octadecyloxy)phenyl)methanol and Fmoc-Lys(Boc)-OH, Fmoc-Val-OH or Fmoc-Ala-OH is completed, the method further comprises the step of adding 4-methylpiperidine to react.

6. Use of the triazole-modified cyclic peptide Triazole-Cathelicidin-NV, Triazole-Cathelicidin-DM or Triazole-Tylotoin of the amphibian-derived antimicrobial peptide according to claim 1 in the preparation of medical products, skin care products or cosmetics.

7. A composition, characterized in that: The invention comprises the triazole-modified cyclic peptide of the amphibian-derived antimicrobial peptide as claimed in claim 1 and a carrier.

8. The composition according to claim 7, characterized in that: In the composition, the mass percentage of the triazole-modified cyclic peptide of the amphibian-derived antimicrobial peptide is 0.1%-90%, preferably 0.1%-80%, more preferably 0.1%-70%, further preferably 0.1%-50%, and can be 1%-40%.

9. The composition according to claim 8, characterized in that: The carrier includes an oil phase, an aqueous phase and / or an excipient.

10. The composition according to claim 9, characterized in that: The oil phase is selected from one or a combination of vegetable oil, animal oil, fat, higher fatty acid, ester, hydrocarbon, wax or higher alcohol; Preferably, the excipient is selected from one or a combination of a binder, a filler, a disintegrant, a preservative, a chelating agent, a thickener, a gelling agent, an emollient, an emulsifier, an antioxidant, a penetration enhancer or a stabilizer; Preferably, the composition is in the form of a solution, gel, emulsion, cream, paste, plaster, ointment, lyophilized powder, patch, suspension, wipe or foam.